The latest biotech news

News and Trends 14 Jul 2023

Calliditas reveals ‘encouraging results’ from head and neck cancer trial

Calliditas Therapeutics AB has announced interim data from its proof-of-concept phase 2 trial in patients with squamous cell carcinoma of the head and neck (SCCHN) with its lead NOX 1 and 4 inhibitor product candidate, setanaxib. The analysis reflects encouraging early clinical progression-free survival (PFS) results and is supportive of the presumed anti fibrotic mode […]

July 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 13 Jul 2023

Partnership to progress neurodegenerative disorder treatments

IRBM, Rainwater Charitable Foundation (RCF, Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) are starting a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and […]

July 13, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 13 Jul 2023

Gene therapy company EG 427 raises €18M

EG 427, a French biotechnology company leading the development of pinpoint DNA medicine solutions, has announced the final closing of a Series A financing. The gene therapy company raised an additional €5 million ($5.6 million) in the final closing from a combination of existing investors and new family office investors, bringing the total raised in […]

July 13, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

New venture capital company Biovance Capital Partners launches

Bionova Capital has started a new venture capital company, Biovance Capital Partners. Bionova Capital is a healthcare-focused investor in early-stage life science companies across Europe. Founded in 2015, Bionova Capital actively manages a portfolio of five companies, two in Portugal, two in the U.K., and one in Spain. The new, independent company is fully owned […]

July 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

ADC Therapeutics pauses clinical trial following patient deaths

ADC Therapeutics SA has announced a voluntary pause in the enrollment of new patients in the phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The action was taken by ADC Therapeutics after a recent review of aggregate data […]

July 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

Pfizer kicks $25M into CellCentric

U.K.-based biotechnology company CellCentric has received a strategic investment from Pfizer including $25 million to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer. Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific hematological malignancies, through […]

July 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jul 2023

Crossbow Therapeutics launches with $80M to target cancer

Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding. The round was led by MPM BioImpact and Pfizer Ventures, with participation from Polaris Partners, BVF Partners, Eli Lilly and Company, Mirae Asset Venture […]

July 12, 2023 - 2 minutesmins - By Jim Cornall

Dr. Grégoire Stik, group leader at the Josep Carreras Leukaemia Research Institute and co-author of the study.

News and Trends 11 Jul 2023

Immune memory research could lead to next generation of epigenetic drugs

A team of researchers has discovered that the memory of the immune system relies on characteristic epigenetic features and a specific 3D arrangement of the DNA in the nucleus of memory cells, allowing for a fast activation of these cells. These features are altered in chronic inflammation diseases like asthma and could be important in […]

July 11, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jul 2023

NodThera first to show reduction in neuroinflammation with inflammasome inhibitor

NodThera has announced positive, initial data from four subjects in the elderly volunteer stage of its phase Ib/IIa study evaluating the effects of its lead candidate NT-0796 on inflammatory and disease-specific biomarkers in the blood and cerebrospinal fluid (CSF). NodThera is a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Alan […]

July 11, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Jul 2023

NK:IO awarded £1.6M grant to develop NK cell therapy

NK:IO, a U.K. company working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumors, has been awarded £1.6 million ($2.1 million) in grant funding from Innovate UK’s New Cancer Therapeutics program. The funding will support preclinical development, including development of a manufacturing process in collaboration […]

July 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Jul 2023

Inhaled mRNA medicines redefine respiratory disease treatment

By Carsten Rudolph, co-founder and CEO of Ethris Advancements in mRNA technology have led to the development of inhaled mRNA medicines, which hold tremendous potential for revolutionizing the treatment of respiratory diseases, an area with high unmet needs. However, the primary hurdle in its clinical application lies in the identification of a delivery system that […]

July 11, 2023 - 3 minutesmins - By External Contributor

News and Trends 10 Jul 2023

Existing cancer drug could be repurposed to fight certain aggressive cancers

A team of scientists led by Nanyang Technological University, Singapore (NTU Singapore) has found that an existing cancer drug could be repurposed to target a subset of cancers that currently lack targeted treatment options and is often associated with poor outcomes.This subset of cancers makes up 15% of all cancers and is especially prevalent in […]

July 10, 2023 - 5 minutesmins - By Jim Cornall

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Calliditas reveals ‘encouraging results’ from head and neck cancer trial

Partnership to progress neurodegenerative disorder treatments

Gene therapy company EG 427 raises €18M

New venture capital company Biovance Capital Partners launches

ADC Therapeutics pauses clinical trial following patient deaths

Pfizer kicks $25M into CellCentric

Crossbow Therapeutics launches with $80M to target cancer

Immune memory research could lead to next generation of epigenetic drugs

NodThera first to show reduction in neuroinflammation with inflammasome inhibitor

NK:IO awarded £1.6M grant to develop NK cell therapy

Inhaled mRNA medicines redefine respiratory disease treatment

Existing cancer drug could be repurposed to fight certain aggressive cancers

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!